Health Care • Medicinal Chemicals and Botanical Products
$1.13 ▼ +0.00
(-0.01%)
MKT CAP: $9.2M • VOL: 1.4K
52W L $1 52W H $2
ROARABLE / RQD
D • 45/100
PIOTROSKI
3 / 9
BON // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-09-30 | FY 2024
FILED 2024-09-30 | FY 2023
FILED 2023-09-30 |
|---|---|---|---|
| Revenue (Total Sales) | $18.7M | $23.8M | $29.5M |
| YoY Revenue Growth % | -21.7% | -19.2% | — |
| Gross Profit | $3.9M | $7.1M | — |
| Gross Margin % | 20.8% | 29.8% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$1.6M | $1.9M | $5.9M |
| Operating Margin % | -8.7% | 7.9% | 20.1% |
| Net Income (GAAP) | -$2.0M | $398.2K | $4.6M |
| EBITDA (Normalized) | -$1.6M | $1.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $141.1K | -$7.7M | -$616.9K |
| Capital Expenditures (CapEx) | $6.8K | $7.0K | — |
| Free Cash Flow (FCF) | $134.3K | -$7.7M | -$616.9K |
| FCF Margin % | 0.7% | -32.4% | -2.1% |
| Return on Invested Capital (ROIC %) | — | — | — |
| Cash & Short-Term Equivalents | — | — | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | — | — | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BON.